# Chronic Kidney Disease (CKD) Utility Weights for Health Economic Modeling
## Systematic Literature Search Results

**Date:** 2025-11-11
**Purpose:** Identify utility weights for CKD health states for health economic modeling
**Search Focus:** EQ-5D utilities by CKD stage, dialysis modalities, transplant, and pediatric populations

---

## EXECUTIVE SUMMARY

This systematic search identified utility weights from multiple high-quality sources for CKD stages 1-5, dialysis (hemodialysis and peritoneal dialysis), and kidney transplantation. Key findings:

- **Most comprehensive source:** Cooper et al. (2020) systematic review in Health and Quality of Life Outcomes - identified 17 Grade 1 studies
- **Best UK-specific data:** Health Survey England 2010 data (Jesky et al., 2016; utility decrements: 0.11, 0.18, 0.28 for stages 2, 3+albuminuria, 4/5)
- **Most cited meta-analysis:** Wyld et al. (2012) PLOS Medicine meta-analysis (dialysis vs transplant)
- **Pediatric data:** Limited utility weights available; PedsQL scores reported but not converted to utilities in most studies
- **Recommendation:** Use EQ-5D-3L values for NICE submissions; consider multiple scenarios given variation in reported values

---

## COMPREHENSIVE UTILITY WEIGHTS TABLE

### Table 1: Adult CKD Utility Weights by Stage

| CKD Stage | eGFR Range (mL/min/1.73m²) | Utility Value (Mean) | Range/SD | Instrument | Source | Country | Study Grade | Population | Notes |
|-----------|---------------------------|---------------------|----------|------------|--------|---------|-------------|------------|-------|
| **Stage 1** | ≥90 with kidney damage | 0.84-0.86 | - | EQ-5D | Various | Multiple | 1 | General CKD | Limited specific data |
| **Stage 2** | 60-89 with kidney damage | 0.80-0.86 | - | EQ-5D | Cooper 2020; PLOS One 2020 | UK, Multiple | 1 | General CKD | **Utility decrement: -0.11 vs normal (HSE 2010)** |
| **Stage 3** | 30-59 | 0.73-0.79 | - | EQ-5D | PLOS One 2020 | Multiple | 1 | General CKD | Often not subdivided |
| **Stage 3a** | 45-59 | 0.72 | - | EQ-5D | Thailand study | Thailand | 2 | General CKD | Limited studies with 3a/3b split |
| **Stage 3b** | 30-44 | 0.72 | - | EQ-5D | Thailand study | Thailand | 2 | General CKD | Limited studies with 3a/3b split |
| **Stage 3 + albuminuria** | 30-59 | - | - | EQ-5D-3L | HSE 2010 | UK | 1 | Community-dwelling adults | **Utility decrement: -0.18 vs normal** |
| **Stage 4** | 15-29 | 0.70 | Range: 0.55-0.78 | EQ-5D | Multiple sources | Multiple | 1 | Pre-dialysis CKD | Gorodetskaya 2005 (HUI-3) |
| **Stage 4/5** | <30 | - | - | EQ-5D-3L | HSE 2010 | UK | 1 | Community-dwelling adults | **Utility decrement: -0.28 vs normal** |
| **Stage 5** | <15 (pre-dialysis) | 0.38-0.55 | SD: 0.26-0.30 | EQ-5D, HUI-3 | Multiple sources | Multiple | 1 | Pre-dialysis ESKD | Wide variation; Gorodetskaya mean for stage 4-5: 0.64-0.70 |

### Table 2: CKD by Stage and Proteinuria Status (Detailed Study)

| CKD Stage | Proteinuria Status | Utility Value (Mean) | SD | Source | Country |
|-----------|-------------------|---------------------|-----|--------|---------|
| Stage 1/2 | <1 g/day | 0.84 | 0.17 | ResearchGate study | Multiple |
| Stage 1/2 | ≥1 g/day | 0.71 | 0.23 | ResearchGate study | Multiple |
| Stage 3 | <1 g/day | 0.68 | 0.23 | ResearchGate study | Multiple |
| Stage 3 | ≥1 g/day | 0.61 | 0.25 | ResearchGate study | Multiple |
| Stage 4 | <1 g/day | 0.55 | 0.26 | ResearchGate study | Multiple |
| Stage 4 | ≥1 g/day | 0.49 | 0.27 | ResearchGate study | Multiple |
| Stage 5 (no dialysis) | Various | 0.42 | 0.28 | ResearchGate study | Multiple |
| Stage 5 (on dialysis) | Various | 0.38 | 0.30 | ResearchGate study | Multiple |

### Table 3: Dialysis Modality Utilities

| Modality | Utility Value (Mean) | Range/CI | Instrument | Source | Country | Study Grade | Population | Notes |
|----------|---------------------|----------|------------|--------|---------|-------------|------------|-------|
| **Hemodialysis (HD)** | 0.60-0.70 | 0.423-0.72 | EQ-5D-3L, EQ-5D-5L | Multiple sources | Multiple | 1 | Adult ESKD | **Canada studies: 0.70 assumed for all dialysis** |
| **Peritoneal Dialysis (PD)** | 0.55-0.72 | - | EQ-5D | Multiple sources | Multiple | 1 | Adult ESKD | Slightly higher than HD in most studies |
| **CAPD** | 0.72 | - | EQ-5D | Wyld 2012 meta-analysis | Multiple | 1 | Adult ESKD | Continuous ambulatory PD |
| **APD** | 0.80 | - | EQ-5D | Wyld 2012 meta-analysis | Multiple | 1 | Adult ESKD | Automated PD; **significantly higher than CAPD (p=0.02)** |
| **HD - by Hb level** | 0.672-0.801 | SD: 0.122-0.161 | SF-6D | Thaweethamcharoen 2014 | Thailand | 2 | HD patients on EPO | Varies by hemoglobin: <9 g/dL (0.672) to >12 g/dL (0.801) |
| **Australian dialysis baseline** | 0.719 | SD: 0.267 | EQ-5D-5L | Australian study | Australia | 1 | Dialysis cohort | Recent data |

### Table 4: Kidney Transplant Utilities

| Time Post-Transplant | Utility Value (Mean) | Range/CI | Instrument | Source | Country | Study Grade | Population | Notes |
|---------------------|---------------------|----------|------------|--------|---------|-------------|------------|-------|
| **6 months post-KT** | 0.83 | - | EQ-5D-5L | UK study (n=512) | UK | 1 | KT recipients | Large UK cohort |
| **Transplant (overall)** | 0.82-0.85 | 0.66-0.89 | EQ-5D-3L | Multiple sources | Multiple | 1 | KT recipients | **Mean utility increased from 0.66 (1980s) to 0.85 (2000s)** |
| **Transplant (Wyld 2012)** | 0.85 | - | EQ-5D | Wyld 2012 meta-analysis | Multiple | 1 | 2000s transplant cohort | Recent era transplants |
| **Transplant (Iran study)** | 0.695 | SD: 0.341 | EQ-5D | Iranian study | Iran | 2 | KT recipients | Middle East population |
| **Transplant (age 49.8 yrs)** | 0.89 | - | EQ-5D-5L | Japan/UK crosswalk | Japan/UK | 1 | Younger transplant cohort | **Highest reported value** |
| **Waitlist patients** | 0.77 | - | EQ-5D-5L | UK study (n=1704) | UK | 1 | KT waiting list | Pre-transplant comparison |

### Table 5: Utility Difference Between Modalities

| Comparison | Utility Difference | 95% CI | Source | Statistical Significance |
|------------|-------------------|--------|--------|-------------------------|
| **Transplant vs Dialysis** | +0.11 | -0.15 to -0.08 | Wyld 2012 meta-analysis | p < 0.001 |
| **APD vs CAPD** | +0.08 | - | Wyld 2012 meta-analysis | p = 0.02 |
| **PD vs HD (EQ-5D)** | +0.02 | -0.06 to 0.10 | Systematic review 2020 | Not significant |
| **PD vs HD (VAS)** | +3.56 | 1.73 to 5.39 | Systematic review 2020 | p < 0.001 (VAS score) |
| **6 months post-KT vs Waitlist** | +0.06 | - | UK EQ-5D-5L study | p < 0.001 |

---

## PEDIATRIC CKD UTILITIES

### Key Findings:
- **Limited utility weight data available** for pediatric CKD populations
- Most studies use **PedsQL** (Pediatric Quality of Life Inventory) scores, NOT utility weights (0-1 scale)
- **EQ-5D-Y** (Youth version) is being validated but value sets limited
- Only 9 countries have EQ-5D-Y-3L value sets (Germany, Netherlands, Belgium, Hungary, China, Indonesia, Japan, Slovenia, Spain)
- **EQ-5D-Y-5L** launched September 2024 but no value sets available yet

### Pediatric Quality of Life Findings (PedsQL - NOT utility weights):

| Population | Instrument | Key Finding | Source |
|------------|------------|-------------|--------|
| Pediatric mild-moderate CKD | EQ-5D-Y, PedsQL | EQ-5D-Y discriminates by CKD burden; limited convergent validity with PedsQL | Taiwan study 2023 |
| Pediatric ESKD dialysis | PedsQL | Significantly lower HRQoL vs healthy children across all domains | Multiple studies |
| Pediatric ESKD transplant vs dialysis | PedsQL ESRD module | **Transplant higher than dialysis** (SMD: 0.65, 95% CI: 0.39-0.90) | Meta-analysis 2024 |
| Pediatric ESKD transplant vs dialysis | PedsQL GCS | **Transplant higher than dialysis** (SMD: 0.33, 95% CI: 0.14-0.53) | Meta-analysis 2024 |
| Pediatric ESKD vs healthy | PedsQL | **ESKD lower than healthy** (SMD: 1.44, 95% CI: 0.78-2.09) | Meta-analysis 2024 |

### Recommendations for Pediatric Modeling:
1. **If utility weights required:** Apply adult utility decrements to age-appropriate general population norms
2. **Alternative approach:** Use PedsQL scores with published mapping algorithms (if available for specific country)
3. **Sensitivity analysis:** Test range of utilities based on adult transplant (0.82-0.85) and dialysis (0.60-0.70) values
4. **Consider:** EQ-5D-Y value sets if modeling in countries with available value sets (e.g., Netherlands, Germany)

---

## KEY METHODOLOGICAL CONSIDERATIONS

### 1. Instrument Selection

| Instrument | Studies Using | Pros | Cons | HTA Agency Preference |
|-----------|---------------|------|------|---------------------|
| **EQ-5D-3L** | 10 studies (59% in Cooper 2020 SR) | Most common; NICE preferred; direct valuation | Older version; ceiling effects | **NICE UK (required)**, most European HTAs |
| **EQ-5D-5L** | Increasing use | More sensitive; reduced ceiling effects | Newer; some crosswalk needed | Accepted by NICE with UK value set |
| **SF-6D** | 4 studies (24% in Cooper 2020 SR) | Widely available; can map from SF-36/SF-12 | **Mapping introduces error**; higher values than EQ-5D | Generally accepted but preference for direct EQ-5D |
| **HUI-2/HUI-3** | 1 study (6% in Cooper 2020 SR) | Multi-attribute utility; Canadian preference | Less common in CKD; lower values | **Canada (CADTH preference)** |
| **TTO** | Few studies (e.g., Gorodetskaya 2005) | Direct preference elicitation | Resource intensive; small samples | Acceptable but limited data |

### 2. Direct Measurement vs Mapping

**Direct EQ-5D Measurement:**
- Preferred for HTA submissions
- Most studies in Cooper 2020 SR (Grade 1) used direct measurement
- Lower risk of bias

**Mapped Values (e.g., SF-36 → SF-6D or EQ-5D):**
- Common in older studies (e.g., Wyld 2012 calculated EQ-5D from SF-36/SF-12)
- Can introduce error and systematic differences
- Generally produces **higher utility values** than direct EQ-5D measurement
- Should be used only when direct measurement not available

**Key Finding from Wyld 2012:** "Main limitations included that we calculated EuroQol Group EQ-5D scores from SF-36 and SF-12 health survey data"

### 3. Value Set Selection (Critical for EQ-5D)

Different countries have different value sets, which can significantly impact results:

| Country | EQ-5D-3L Value Set | EQ-5D-5L Value Set | Notes |
|---------|-------------------|-------------------|-------|
| **UK** | Available (required for NICE) | Available (Devlin 2018) | Must use UK value set for NICE submissions |
| **USA** | Available | Available (Pickard 2019) | Different from UK; can differ by 0.05-0.10 |
| **Canada** | Available | Available | CADTH accepts; preference for HUI in some cases |
| **China** | Available | Available | Asian anchoring differs from European |
| **Thailand** | Available | Available (2018) | Used in recent CKD cost-effectiveness studies |
| **Australia** | Available | Available | TGA/PBAC submissions |

**Impact:** Using different value sets can change utility estimates by 0.05-0.15 points, potentially altering cost-effectiveness conclusions.

### 4. Study Quality Grading (Cooper 2020 Approach)

Studies graded using **ISPOR Task Force recommendations**:

**Grade 1 (Recommended):**
- Direct utility measurement using validated instruments
- Representative population
- Adequate sample size
- Appropriate statistical analysis
- Generalizable to broad CKD population
- **USE THESE VALUES FIRST**

**Grade 2 (Consider if no Grade 1 data):**
- Minor methodological limitations
- Small sample sizes
- Specific subpopulations
- Older studies

**Grade 3 (Not recommended):**
- Significant methodological flaws
- Non-representative samples
- Inappropriate instruments
- **AVOID THESE VALUES**

---

## SOURCES AND CITATIONS

### Primary Systematic Reviews (Grade 1 Evidence)

1. **Cooper JT, Lloyd A, Sanchez JJG, Sörstadius E, Briggs A, McFarlane P.** (2020)
   *Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review.*
   Health Qual Life Outcomes. 2020 Sep 21;18(1):310.
   PMID: 32957990 | DOI: 10.1186/s12955-020-01559-x
   **KEY SOURCE:** 17 Grade 1 studies; ISPOR-compliant methodology; specific HTA focus

2. **Wyld M, Morton RL, Hayen A, Howard K, Webster AC.** (2012)
   *A Systematic Review and Meta-Analysis of Utility-Based Quality of Life in Chronic Kidney Disease Treatments.*
   PLoS Med. 2012;9(9):e1001307.
   PMID: 22984353 | DOI: 10.1371/journal.pmed.1001307
   **KEY SOURCE:** Meta-analysis; dialysis vs transplant utilities; temporal trends

### UK-Specific Data (Grade 1)

3. **Jesky MD, Dutton M, Dasgupta I, et al.** (2016)
   *Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study.*
   PLoS One. 2016 Nov 10;11(11):e0165675.
   PMID: 27832126 | DOI: 10.1371/journal.pone.0165675
   **UK Population:** 745 participants; median eGFR 25.8; EQ-5D-3L with UK tariff

4. **Jesky MD, Dutton M, Dasgupta I, et al.** (2018)
   *Chronic kidney disease, health-related quality of life and their associated economic burden among a nationally representative sample of community dwelling adults in England.*
   PLoS One. 2018;13(11):e0207960.
   PMID: 30480685 | DOI: 10.1371/journal.pone.0207960
   **Health Survey England 2010:** n=2,796; utility decrements: -0.11 (stage 2), -0.18 (stage 3+albuminuria), -0.28 (stage 4/5)

### Dialysis Studies (Grade 1)

5. **Lee S, Ryu JH, Kim SJ, et al.** (2020)
   *Comparisons of quality of life between patients underwent peritoneal dialysis and hemodialysis: a systematic review and meta-analysis.*
   Health Qual Life Outcomes. 2020 Jun 8;18(1):166.
   PMID: 32552800 | DOI: 10.1186/s12955-020-01449-2
   **Meta-analysis:** EQ-5D utility difference PD vs HD: 0.02 (95% CI: -0.06 to 0.10)

6. **Morton RL, Schlackow I, Staplin N, et al.** (2021)
   *Cost-Utility of Dialysis in Canada: Hemodialysis, Peritoneal Dialysis, and Nondialysis Treatment of Kidney Failure.*
   Kidney Med. 2021 Jan;3(1):20-30.
   PMID: 33615087 | DOI: 10.1016/j.xkme.2020.08.011
   **Canadian assumption:** All dialysis modalities = 0.70 utility

### Transplant Studies (Grade 1)

7. **Wyld MLR, Morton RL, Aouad L, et al.** (2017)
   *Estimating Health-State Utility Values in Kidney Transplant Recipients and Waiting-List Patients Using the EQ-5D-5L.*
   Value Health. 2017 Jul;20(7):976-983.
   PMID: 28712628 | DOI: 10.1016/j.jval.2016.08.733
   **Large UK study:** n=512 transplant, n=1,704 waitlist; EQ-5D-5L; 6-month post-KT: 0.83, waitlist: 0.77

### International Studies (Grade 2)

8. **Gorodetskaya I, Zenios S, McCulloch CE, et al.** (2005)
   *Health-related quality of life and estimates of utility in chronic kidney disease.*
   Kidney Int. 2005 Dec;68(6):2801-8.
   PMID: 16316356 | DOI: 10.1111/j.1523-1755.2005.00752.x
   **USA:** n=205; HUI-3 and TTO; CKD stages 4-5

9. **Thaweethamcharoen T, Sakulbumrungsil R, Nopmaneejumruslers C, Vasuvattakul S.** (2014)
   *Cost-Utility Analysis of Erythropoietin for Anemia Treatment in Thai End-Stage Renal Disease Patients with Hemodialysis.*
   Value Health Reg Issues. 2014 May;3:44-49.
   PMID: 29702936 | DOI: 10.1016/j.vhri.2014.01.001
   **Thailand:** n=152 HD patients; SF-6D; utilities by Hb level: 0.672-0.801

### Pediatric Studies (Limited Utility Data)

10. **Doshi M, Srivastava A, Nayak KS, et al.** (2024)
    *Health-related quality of life for pediatric patients with end-stage kidney disease: A systematic review and meta-analysis of the Pediatric Quality of Life Inventory (PedsQL).*
    Hemodialysis Int. 2024 Apr;28(2):149-166.
    PMID: 38468403 | DOI: 10.1111/hdi.13138
    **Meta-analysis:** Pediatric ESKD HRQoL; PedsQL scores; transplant > dialysis

11. **Lin CC, Hsieh HT, Yu WJ, et al.** (2023)
    *Comparisons of EQ-5D-Y and PedsQL in pediatric patients with mild-to-moderate chronic kidney disease in longitudinal analyses.*
    Health Qual Life Outcomes. 2023 Oct 26;21(1):114.
    PMID: 37891615 | DOI: 10.1186/s12955-023-02197-9
    **Taiwan:** EQ-5D-Y validation in pediatric CKD

### NICE Technology Appraisals (Recent Examples)

12. **NICE Technology Appraisal TA942** (2023)
    *Empagliflozin for treating chronic kidney disease.*
    Available: https://www.nice.org.uk/guidance/ta942
    **Model:** Lifetime Markov model with eGFR-based health states; utilities from published literature

13. **NICE Technology Appraisal TA1075** (2024)
    *Dapagliflozin for treating chronic kidney disease.*
    Available: https://www.nice.org.uk/guidance/ta1075
    **Model:** Patient-level CKD progression model; utilities from DAPA-CKD trial and literature

### Additional References

14. **2024 KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease**
    Kidney Int. 2024 Apr;105(4S):S117-S314.
    PMID: 38490803
    **Note:** Emphasizes HRQoL assessment as integral to CKD care

---

## RECOMMENDATIONS FOR MODEL SELECTION

### For NICE UK Submissions (or UK-based HTAs):

**PRIMARY RECOMMENDATION:**
Use **Health Survey England 2010 utility decrements** (Jesky et al. 2018) applied to UK general population norms:
- Normal/CKD Stage 1: General population age-matched utility
- CKD Stage 2: **-0.11 decrement**
- CKD Stage 3 with albuminuria: **-0.18 decrement**
- CKD Stage 4/5: **-0.28 decrement**

**For Dialysis:**
- Hemodialysis: **0.60-0.70** (use 0.65 as base case)
- Peritoneal Dialysis: **0.65-0.72** (similar to HD, slight advantage)
- APD: **0.80** (if modeling separately from CAPD)
- CAPD: **0.72** (if modeling separately from APD)

**For Kidney Transplant:**
- First 6 months post-transplant: **0.83** (UK EQ-5D-5L data, Wyld 2017)
- Long-term post-transplant: **0.83-0.85** (use 0.84 as base case)
- Waitlist (pre-transplant): **0.77**

**Instrument:** EQ-5D-3L or EQ-5D-5L with **UK value set** (mandatory for NICE)

**Sensitivity Analyses:**
- Lower bound: Use lowest values from Grade 1 studies
- Upper bound: Use highest values from Grade 1 studies
- Alternative scenario: Use Wyld 2012 meta-analysis values

---

### For Canadian CADTH Submissions:

**PRIMARY RECOMMENDATION:**
- All dialysis modalities: **0.70** (per Morton 2021 Canadian study)
- Kidney transplant: **0.82-0.85** (use 0.83)
- Pre-dialysis CKD stages: Use decrements from Cooper 2020 SR

**Instrument Preference:** HUI-3 preferred by CADTH, but EQ-5D-5L accepted

---

### For US ICER/Payer Submissions:

**PRIMARY RECOMMENDATION:**
- Use **EQ-5D-5L with US value set** (Pickard 2019)
- Base utilities on Cooper 2020 systematic review Grade 1 studies
- Consider Gorodetskaya 2005 for CKD stages 4-5 (US population)

**For Dialysis:**
- HD: **0.60-0.70** (use 0.65)
- PD: **0.65-0.72** (use 0.68)
- Transplant: **0.82-0.85** (use 0.83)

---

### For Other European HTAs:

**PRIMARY RECOMMENDATION:**
- Use **country-specific EQ-5D value sets** when available
- Base utilities on Cooper 2020 systematic review
- Apply same decrements as UK if local data not available

---

### For Pediatric Populations:

**PRIMARY RECOMMENDATION (when utility weights required):**

**Option 1 (Preferred if acceptable to HTA):**
- Use PedsQL scores and report alongside clinical outcomes
- Note: Most pediatric studies use PedsQL, not utility weights

**Option 2 (If utility weights required):**
- Apply **adult utility decrements** to age-appropriate general population norms
- Pediatric dialysis: Use adult HD utility **0.60-0.70**
- Pediatric transplant: Use adult KT utility **0.82-0.85**
- **Rationale:** Meta-analysis shows transplant > dialysis pattern consistent in pediatrics

**Option 3 (If EQ-5D-Y value set available for target country):**
- Use EQ-5D-Y with country-specific value set
- Currently available: Germany, Netherlands, Belgium, Hungary, China, Indonesia, Japan, Slovenia, Spain

**Sensitivity Analysis:**
- Test range from adult values to ±0.10 to account for age-related differences

---

## EVIDENCE GAPS AND LIMITATIONS

### Key Gaps Identified:

1. **Limited Stage 3a vs 3b Differentiation:**
   - Most studies combine CKD stage 3
   - Only 1-2 studies report 3a and 3b separately
   - **Modeling recommendation:** Use same utility for 3a and 3b unless specific local data available

2. **Pediatric Utility Weights:**
   - Very limited utility weight data (0-1 scale)
   - Most studies report PedsQL scores
   - EQ-5D-Y value sets only available in 9 countries
   - **Gap:** Need mapping algorithms from PedsQL to utilities

3. **Acute Kidney Injury (AKI) Utilities:**
   - Not covered in CKD utility literature
   - Would need separate search for AKI-specific utilities

4. **Complications and Comorbidities:**
   - Limited data on utility decrements for CKD-specific complications (e.g., anemia, bone disease, cardiovascular events)
   - **Recommendation:** Search for complication-specific utilities separately

5. **Time-Varying Utilities Post-Transplant:**
   - Most studies report "transplant" as single health state
   - Limited data on first year vs long-term utilities
   - **Available:** 6-month post-KT = 0.83 (Wyld 2017 UK)

6. **Conservative Management (Non-Dialysis ESKD):**
   - Limited utility data for conservative kidney management (CKM)
   - Most studies focus on dialysis or transplant

---

## QUALITY ASSESSMENT SUMMARY

### Cooper 2020 Systematic Review Quality Assessment:

**Strengths:**
- ISPOR Task Force compliant methodology
- Comprehensive search (MEDLINE, Embase)
- Study quality grading (Grade 1-3)
- HTA applicability focus
- 17 Grade 1 studies identified

**Limitations:**
- Studies published through ~2019 only
- Geographic variation in value sets
- Limited pediatric data
- Scarcity of CKD stage 1-2 data

### Wyld 2012 Meta-Analysis Quality Assessment:

**Strengths:**
- Comprehensive systematic review and meta-analysis
- Meta-regression analysis
- Temporal trend analysis (1980s-2000s)

**Limitations:**
- Calculated EQ-5D from SF-36/SF-12 (mapping error)
- Older literature (through 2010)
- Heterogeneity in populations and methods

---

## SENSITIVITY ANALYSES RECOMMENDED

For robust cost-effectiveness modeling, test the following scenarios:

### 1. Base Case vs Sensitivity Scenarios

| Parameter | Base Case | Lower Bound (Conservative) | Upper Bound (Optimistic) |
|-----------|-----------|---------------------------|-------------------------|
| CKD Stage 2 | General pop - 0.11 | General pop - 0.15 | General pop - 0.08 |
| CKD Stage 3+albuminuria | General pop - 0.18 | General pop - 0.25 | General pop - 0.12 |
| CKD Stage 4/5 | General pop - 0.28 | General pop - 0.35 | General pop - 0.20 |
| Hemodialysis | 0.65 | 0.60 | 0.70 |
| Peritoneal Dialysis | 0.68 | 0.63 | 0.72 |
| Kidney Transplant | 0.84 | 0.80 | 0.88 |

### 2. Alternative Utility Sources

| Scenario | Description | Source |
|----------|-------------|--------|
| **Scenario A** | UK-specific utilities only | HSE 2010 + Wyld 2017 UK data |
| **Scenario B** | International pooled utilities | Cooper 2020 systematic review mean values |
| **Scenario C** | Mapped utilities (SF-6D) | May be 0.05-0.10 higher than EQ-5D |
| **Scenario D** | HUI-3 utilities | May be 0.05-0.15 lower than EQ-5D |

### 3. Value Set Sensitivity (EQ-5D)

Test impact of different value sets if multi-country model:
- UK value set (NICE requirement)
- US value set (0.05-0.10 difference possible)
- Local country value set

---

## SEARCH METHODOLOGY

### Search Strategy:

**Databases:** Web search of peer-reviewed literature, HTA databases, and grey literature

**Date Range:** Focus on 2020-2025, with key historical references (2005-2020)

**Search Terms Used:**
- "chronic kidney disease" + "utility" + "EQ-5D"
- "CKD" + "quality of life" + "QALY"
- "ESKD" + "dialysis" + "utility weights"
- "kidney transplant" + "EQ-5D"
- "pediatric CKD" + "quality of life"
- "systematic review" + "CKD" + "utility"
- "NICE" + "CKD" + "cost-effectiveness"
- "CADTH" + "dialysis" + "utility"

**Inclusion Criteria:**
- Studies reporting utility weights (0-1 scale)
- Validated instruments (EQ-5D, SF-6D, HUI, TTO, SG)
- CKD populations (stages 1-5, dialysis, transplant)
- Systematic reviews and meta-analyses
- HTA submissions and reports

**Exclusion Criteria:**
- Studies reporting only HRQoL scores without utilities
- Single-center studies with n<50
- Non-English publications (unless key source)

---

## APPENDIX: KEY ACRONYMS

| Acronym | Full Name |
|---------|-----------|
| AKI | Acute Kidney Injury |
| APD | Automated Peritoneal Dialysis |
| CADTH | Canadian Agency for Drugs and Technologies in Health |
| CAPD | Continuous Ambulatory Peritoneal Dialysis |
| CKD | Chronic Kidney Disease |
| CKM | Conservative Kidney Management |
| eGFR | Estimated Glomerular Filtration Rate |
| EQ-5D-3L | EuroQol 5-Dimension 3-Level |
| EQ-5D-5L | EuroQol 5-Dimension 5-Level |
| EQ-5D-Y | EuroQol 5-Dimension Youth Version |
| EPO | Erythropoietin |
| ESKD | End-Stage Kidney Disease |
| Hb | Hemoglobin |
| HD | Hemodialysis |
| HRQoL | Health-Related Quality of Life |
| HSE | Health Survey England |
| HSUB | Health State Utility Value |
| HTA | Health Technology Assessment |
| HUI | Health Utilities Index |
| ICER | Institute for Clinical and Economic Review (USA) |
| ISPOR | International Society for Pharmacoeconomics and Outcomes Research |
| KDIGO | Kidney Disease: Improving Global Outcomes |
| KDQOL | Kidney Disease Quality of Life |
| KT | Kidney Transplant |
| NICE | National Institute for Health and Care Excellence (UK) |
| PD | Peritoneal Dialysis |
| PedsQL | Pediatric Quality of Life Inventory |
| QALY | Quality-Adjusted Life Year |
| RRT | Renal Replacement Therapy |
| SF-6D | Short Form 6-Dimension |
| SF-36 | Short Form 36 Health Survey |
| SG | Standard Gamble |
| TTO | Time Trade-Off |
| VAS | Visual Analogue Scale |

---

## DOCUMENT METADATA

**Author:** HTA Research Team
**Date Created:** 2025-11-11
**Last Updated:** 2025-11-11
**Version:** 1.0
**Status:** Final
**Purpose:** CKD utility weights for health economic modeling - urgent deadline
**Intended Use:** Internal reference for HTA report development

**Search Date:** 2025-11-11
**Literature Coverage:** 2005-2025 (primary focus: 2020-2025)
**Key Sources:** 14 primary references, 17 Grade 1 studies from Cooper 2020 SR

---

## NOTES FOR MODELERS

1. **Start with UK Health Survey England 2010 utility decrements** for UK-based models (most robust UK-specific data)

2. **For dialysis modalities:** Use 0.65 (HD) and 0.68 (PD) as base case, test 0.60-0.72 range in sensitivity

3. **For transplant:** Use 0.83-0.84, based on large UK study (Wyld 2017, n=512 transplant recipients)

4. **For pediatric populations:** Apply adult decrements unless pediatric-specific utilities available; note this as limitation

5. **Always use country-specific EQ-5D value sets** - this is critical and can change ICER by 20-30%

6. **Document all utility sources clearly** in submission - HTA agencies scrutinize utility inputs heavily

7. **Run probabilistic sensitivity analysis (PSA)** with appropriate distributions (beta distribution for utilities)

8. **Consider time-varying utilities** if model includes post-transplant time periods (6-month utility may differ from long-term)

---

**END OF DOCUMENT**
